NCCN AstraZeneca Early Stage NSCLC Request for Proposals

Funding Agency:
National Comprehensive Cancer Network

National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for NCCN Member Institution faculty. This opportunity is seeking proposals to improve patient care and outcomes in early-stage non-small cell lung cancer (NSCLC). Multiple factors contribute to the complexity of treating the disease, including screening, staging, surgical or other local treatment options, and adjuvant systemic therapy.  


To be considered for funding, Letters of Intent must be submitted by 5:00 pm ET on Monday, May 3, 2021.




Medical - Clinical Science

External Deadline

May 3, 2021